Go Pro
→ Your 10X AI demo is starting… (From TradeSmith) (Ad)tc pixel Free BIO.B Stock Alerts

Bio-Rad Laboratories (BIO.B) Competitors

Bio-Rad Laboratories logo
$337.00 0.00 (0.00%)
As of 08/14/2026
Compare

BIO.B vs. ILMN, MTD, MEDP, CRL, and RVTY

Should you buy Bio-Rad Laboratories stock or one of its competitors? Bio-Rad Laboratories's main competitors and comparable companies include Illumina (ILMN), Mettler-Toledo International (MTD), Medpace (MEDP), Charles River Laboratories International (CRL), and Revvity (RVTY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bio-Rad Laboratories compare to Illumina?

Illumina (NASDAQ:ILMN) and Bio-Rad Laboratories (NYSE:BIO.B) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Illumina has a net margin of 18.36% compared to Bio-Rad Laboratories' net margin of 8.59%. Illumina's return on equity of 29.84% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Illumina18.36% 29.84% 12.17%
Bio-Rad Laboratories 8.59%3.54%2.48%

Illumina currently has a consensus price target of $188.40, indicating a potential downside of 1.30%. Given Illumina's stronger consensus rating and higher possible upside, research analysts clearly believe Illumina is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Illumina
2 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.47
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Illumina has higher revenue and earnings than Bio-Rad Laboratories. Illumina is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$4.34B6.64$850M$5.3635.61
Bio-Rad Laboratories$2.59B3.48$759.90M$8.2540.85

In the previous week, Illumina had 9 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 9 mentions for Illumina and 0 mentions for Bio-Rad Laboratories. Illumina's average media sentiment score of 1.20 beat Bio-Rad Laboratories' score of 0.00 indicating that Illumina is being referred to more favorably in the media.

Company Overall Sentiment
Illumina Positive
Bio-Rad Laboratories Neutral

89.4% of Illumina shares are owned by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. 2.9% of Illumina shares are owned by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Illumina has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Summary

Illumina beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Bio-Rad Laboratories (NYSE:BIO.B) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Mettler-Toledo International has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Mettler-Toledo International has a net margin of 21.91% compared to Bio-Rad Laboratories' net margin of 8.59%. Bio-Rad Laboratories' return on equity of 3.54% beat Mettler-Toledo International's return on equity.

Company Net Margins Return on Equity Return on Assets
Mettler-Toledo International21.91% -1,212.14% 25.11%
Bio-Rad Laboratories 8.59%3.54%2.48%

Mettler-Toledo International has higher revenue and earnings than Bio-Rad Laboratories. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$4.03B7.05$869.19M$44.4331.90
Bio-Rad Laboratories$2.59B3.48$759.90M$8.2540.85

In the previous week, Mettler-Toledo International had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 6 mentions for Mettler-Toledo International and 0 mentions for Bio-Rad Laboratories. Mettler-Toledo International's average media sentiment score of 1.41 beat Bio-Rad Laboratories' score of 0.00 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company Overall Sentiment
Mettler-Toledo International Positive
Bio-Rad Laboratories Neutral

Mettler-Toledo International currently has a consensus target price of $1,461.27, indicating a potential upside of 3.10%. Given Mettler-Toledo International's stronger consensus rating and higher probable upside, equities analysts clearly believe Mettler-Toledo International is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mettler-Toledo International
0 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.46
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Mettler-Toledo International beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Medpace?

Medpace (NASDAQ:MEDP) and Bio-Rad Laboratories (NYSE:BIO.B) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Medpace currently has a consensus target price of $584.18, indicating a potential upside of 0.98%. Given Medpace's stronger consensus rating and higher probable upside, equities analysts plainly believe Medpace is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace
0 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.23
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Medpace had 27 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 27 mentions for Medpace and 0 mentions for Bio-Rad Laboratories. Medpace's average media sentiment score of 0.78 beat Bio-Rad Laboratories' score of 0.00 indicating that Medpace is being referred to more favorably in the media.

Company Overall Sentiment
Medpace Positive
Bio-Rad Laboratories Neutral

78.0% of Medpace shares are held by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bio-Rad Laboratories has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medpace$2.53B6.38$451.12M$17.0633.91
Bio-Rad Laboratories$2.59B3.48$759.90M$8.2540.85

Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Medpace has a net margin of 17.67% compared to Bio-Rad Laboratories' net margin of 8.59%. Medpace's return on equity of 110.15% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Medpace17.67% 110.15% 24.84%
Bio-Rad Laboratories 8.59%3.54%2.48%

Summary

Medpace beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Bio-Rad Laboratories (NYSE:BIO.B) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Charles River Laboratories International has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Bio-Rad Laboratories has a net margin of 8.59% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Charles River Laboratories International-5.96% 15.75% 6.51%
Bio-Rad Laboratories 8.59%3.54%2.48%

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Charles River Laboratories International had 23 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 23 mentions for Charles River Laboratories International and 0 mentions for Bio-Rad Laboratories. Charles River Laboratories International's average media sentiment score of 0.45 beat Bio-Rad Laboratories' score of 0.00 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company Overall Sentiment
Charles River Laboratories International Neutral
Bio-Rad Laboratories Neutral

Bio-Rad Laboratories has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$4.02B3.33-$144.34M-$4.85N/A
Bio-Rad Laboratories$2.59B3.48$759.90M$8.2540.85

Charles River Laboratories International currently has a consensus price target of $255.65, indicating a potential downside of 8.60%. Given Charles River Laboratories International's stronger consensus rating and higher possible upside, research analysts plainly believe Charles River Laboratories International is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Charles River Laboratories International
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Charles River Laboratories International beats Bio-Rad Laboratories on 10 of the 16 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Revvity?

Bio-Rad Laboratories (NYSE:BIO.B) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Revvity has a consensus target price of $108.36, indicating a potential downside of 7.15%. Given Revvity's stronger consensus rating and higher probable upside, analysts clearly believe Revvity is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Revvity
0 Sell rating(s)
12 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

Bio-Rad Laboratories has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Revvity has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Bio-Rad Laboratories has a net margin of 8.59% compared to Revvity's net margin of 8.16%. Revvity's return on equity of 8.34% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories8.59% 3.54% 2.48%
Revvity 8.16%8.34%5.01%

Bio-Rad Laboratories has higher earnings, but lower revenue than Revvity. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.59B3.48$759.90M$8.2540.85
Revvity$2.91B4.47$241.20M$2.1055.58

In the previous week, Revvity had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 6 mentions for Revvity and 0 mentions for Bio-Rad Laboratories. Revvity's average media sentiment score of 0.56 beat Bio-Rad Laboratories' score of 0.00 indicating that Revvity is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Revvity Positive

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 0.9% of Revvity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Revvity beats Bio-Rad Laboratories on 12 of the 16 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIO.B vs. The Competition

Export
MetricBio-Rad LaboratoriesLife Sciences Tools & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$9.02B$9.56B$7.03B$24.33B
Dividend YieldN/A1.46%2.57%3.68%
P/E Ratio40.8560.31271.5430.85
Price / Sales3.48105.43673.8817.93
Price / Cash33.6326.1175.7032.61
Price / Book1.2637.5012.926.82
Net Income$759.90M$56.66B$3.45B$1.06B
7 Day PerformanceN/A0.29%1.17%0.55%
1 Month Performance8.93%2.08%2.18%2.70%
1 Year Performance36.41%17.23%62.39%19.14%

Bio-Rad Laboratories Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIO.B
Bio-Rad Laboratories
N/A$337.00
flat		N/A+36.4%$9.02B$2.59B40.858,200
ILMN
Illumina
3.0171 of 5 stars		$192.13
-0.3%		$188.40
-1.9%		+90.7%$29.02B$4.34B35.868,650
MTD
Mettler-Toledo International
3.1388 of 5 stars		$1,414.09
-1.2%		$1,461.27
+3.3%		+7.7%$28.35B$4.03B31.8418,100
MEDP
Medpace
3.7536 of 5 stars		$578.93
-0.5%		$584.18
+0.9%		+26.4%$16.17B$2.53B33.976,200
CRL
Charles River Laboratories International
1.6899 of 5 stars		$277.80
-1.2%		$255.65
-8.0%		+78.5%$13.26B$4.02BN/A19,700

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:BIO.B) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
"Second Wave” Hitting Iran Soon? Wall Street Issues Warning
Analysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...
TradeSmith | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
One Ticker Tied to a Major White House Move You Should Know
Larry Benedict made 274 million dollars for his clients by spotting major market moves before they happened. ...
Brownstone Research | Sponsoredtc pixel
After KDA, PRE, and OCEAN—this is the one
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel